MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Zacks Research

MiNK Therapeutics (NASDAQ:INKT) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also issued reports on INKT. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research note on Monday, May 18th. Finally, Weiss Ratings upgraded shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $35.00.

MiNK Therapeutics Price Performance

Shares of INKT stock opened at $11.09 on Tuesday. MiNK Therapeutics has a 12-month low of $8.48 and a 12-month high of $30.64. The firm has a market capitalization of $55.25 million, a price-to-earnings ratio of -3.90 and a beta of 0.47. The business has a 50 day simple moving average of $11.50 and a 200 day simple moving average of $11.39.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. On average, equities analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned 0.55% of MiNK Therapeutics as of its most recent SEC filing. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.